VCYT
What one share of Veracyte holds
Services – Medical Laboratories
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer.
Veracyte’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $6.89 |
|---|---|
| Profit | $1.40 |
| Capex (buildings and equipment) | $0.15 |
| Free cash flow | $2.04 |
| Cash and investments | $3.73 |
| Book value | $17.28 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.26 | −$1.09 | $0.15 | −$1.12 | — | $1.76 |
| 2017 | $2.12 | −$0.91 | $0.05 | −$0.76 | — | $1.10 |
| 2018 | $2.49 | −$0.62 | $0.05 | −$0.42 | — | $1.95 |
| 2019 | $2.61 | −$0.27 | $0.06 | −$0.13 | — | $4.83 |
| 2020 | $2.21 | −$0.66 | $0.05 | −$0.24 | — | $7.24 |
| 2021 | $3.23 | −$1.11 | $0.08 | −$0.55 | — | $15.42 |
| 2022 | $4.14 | −$0.51 | $0.12 | −$0.01 | — | $14.94 |
| 2023 | $4.97 | −$1.02 | $0.14 | $0.47 | — | $14.25 |
| 2024 | $5.70 | $0.31 | $0.14 | $0.82 | — | $15.12 |
| 2025 | $6.42 | $0.82 | $0.12 | $1.57 | — | $16.50 |